Senti Biosciences Holdings, Inc.SNTI

Senti Biosciences Holdings, Inc. Segments Disclosure

10-KFiled Mar 20, 20252 min read
Segment Reporting
The Company views operations and manages the business as one operating and reportable segment, which is the research and development of the Company’s gene circuit platform. The Company’s Chief Operating Decision Maker (the “CODM”), its Chief Executive Officer, manages and allocates resources on a consolidated basis. This decision making process reflects the way in which financial information is regularly reviewed and used by the CODM to review budgets and trial related data, decides how to allocate resources and evaluate performance.
The CODM assesses financial performance based on consolidated net loss. The CODM utilizes consolidated net loss by comparing actual results against budgeted amount on a quarterly basis. As part of this process, consolidated net loss is used as a measure of profit or loss in allocating resources and assessing segment performance. The CODM reviews cash and cash equivalents as a measure of segment assets. As of December 31, 2024 and 2023, the Company’s cash and cash equivalents were $48.3 million and $35.9 million, respectively.
A summary of the segment loss, including significant expenses, is as noted in the table below (in thousands).
December 31,
20242023
Revenue
Contract revenue$— $1,978 
Grant income—583
Total revenue$— $2,561 
Operating expenses
Research and development:
External services and supplies$20,795 $13,247 
Personnel related expenses7,694 10,508 
Facilities and other4,889 7,303 
General and administrative:
Personnel related expenses8,379 23,117 
External services and supplies7,624 6,930 
Facilities and other7,507 4,821 
Depreciation and amortization3,838 3,400 
Impairment of long-lived assets313 25,962 
Total operating expenses61,039 95,288 
Loss from operations(61,039)(92,727)
Interest income948 2,864 
Sublease income6,449 2,323 
Other income, net852 4,134 
Segment net loss from continuing operations$(52,790)$(83,406)
Net income from discontinued operations$— $12,348 
Consolidated net loss$(52,790)$(71,058)
Free Sentinel

Want the next Senti Biosciences Holdings, Inc. segments disclosure the moment it drops?

Set a Sentinel and we'll alert you the moment Senti Biosciences Holdings, Inc.'s next filing hits EDGAR. No credit card, your email never gets sold.

Track for free

About Segments Disclosures

Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.

Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.

Other Available Disclosures

Income TaxesRevenueEarnings Per ShareFair ValuePP&ELeasesDebtCommitmentsStock CompensationNew Standards